Navigation Links
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
Date:4/21/2009

by blocking the activity of at least three "inhibitors of apoptosis proteins" or IAPs (including XIAP, c-IAP1, and c-IAP2) to create conditions in which apoptosis can proceed. As such, AT-406 is considered a multi-IAP antagonist. IAPs are key components of the complex cascade of protein signaling that activates enzymes called caspases to initiate breakdown of the cancer cell. AT-406 is thought to mimic the activity of Smac (second mitochondria-derived activator of caspases) by binding to XIAP and preventing it from inhibiting caspase activation. Upon binding, AT-406 induces rapid degradation of cIAP-1/2 proteins and promotes apoptosis through activation of caspase-8 and the death-receptor complex.

AT-406 is in late-stage preclinical development and has demonstrated strong single-agent antitumor activity in multiple xenograft models of human cancer, including breast cancer, pancreatic cancer, prostate cancer, and lung cancer. AT-406 has also been shown to work synergistically with conventional chemotherapeutic and targeted agents (such as tyrosine kinase inhibitors) in preclinical tumor models.

Other Research Including AT-101

Ascenta Therapeutics also announced that researchers from the University of Pennsylvania presented results at AACR from an independent laboratory study examining the role of Bcl-2 homology (BH) family proteins in the development of chemotherapy resistance in neuroblastoma (Abstract # 3269). Using human-derived neuroblastoma cell lines, these investigators demonstrated differential resistance patterns to inhibitors of the Bcl-2 family proteins based on the relative BH proteins expressed (specifically, Mcl-1 or Bcl-2). They showed that Ascenta's small molecule pan-Bcl-2 inhibitor, AT-101, had preferential inhibition in Mcl-1 predominant lines. They concluded that compounds with activity against Mcl-1 may be useful in the treatment of high-risk neuroblastoma and warrant further stu
'/>"/>

SOURCE Ascenta Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
2. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
3. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
6. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
7. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
8. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
9. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
10. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
11. Arno Therapeutics Reports 2008 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 EnGeneIC, Ltd. ... the treatment of cancer through the targeted delivery ... that, together with the Asbestos Disease Research Institute ... New South Wales (NSW) Premier,s Award for Excellence ... are the hospitals that will be involved in ...
(Date:9/15/2014)... State University have developed a technique for controlling the ... voltages, opening the door to a new generation of ... hinges on the fact that the oxide "skin" of ... acts as a surfactant, lowering the surface tension ... researchers used a liquid metal alloy of gallium and ...
(Date:9/15/2014)... of carbon nanotubes is neat, but Rice University scientists are ... in new fibers created at Rice line up like a ... Angel Mart and his colleagues. , The tricky bit, according ... the journal ACS Nano , is keeping the densely ... , Left to their own devices, carbon nanotubes form clumps ...
(Date:9/15/2014)... MORRISVILLE, NC (PRWEB) September 15, 2014 ... newly developed deep imaging OCT system for the optical ... , The EnvisuTM S4410 SDOCT for Contact ... measurements for standard and high complexity contact lens, IOL ... allows imaging of a complete contact lens immersed in ...
Breaking Biology Technology:EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Researchers control surface tension to manipulate liquid metals 2Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2
... High-quality plasmid DNA for all demanding ... Jeff Braman ,Stratagene , A new ... and reliably isolate,high-purity plasmid DNA. The convenient ... flow columns, and alcohol precipitations, while,easily accommodating ...
... versatile kit for site-directed mutagenesis of,large plasmids ... Holly Hogrefe ,Jeff Braman ,Stratagene , ... efficiencies exceeding 80%. We have created a ... The QuikChange XL,site-directed mutagenesis ...
... accurate using the Quantos cell,proliferation assay kit ... LLC , The Quantos cell proliferation ... the number of cells present in,various tissue culture ... well the kit,performed compared to another commercial fluorescence-based ...
Cached Biology Technology:A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 2A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 3A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 4High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 2High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 3High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 4Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 2Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 3Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 4
(Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
(Date:9/15/2014)... indicates that lowland tapir populations may continue to drop ... Researchers from the Office National de la Chasse et ... Diego Zoo Global reviewed data retrieved from camera traps ... years and compared this data to current harvest rates ... hunting tapirs in French Guiana," said Matthias Tobler, a ...
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... has made significant inroads into uncovering the genetic basis ... with overall obesity and 13 that affect fat distribution. ... a million participants, the largest genetic investigation of human ... (Genetic Investigation of ANthropometric Traits) consortium which consists ...
... may be on the way for millions of people on ... bugs. Scientists have reported a key advance in efforts to ... as a major nuisance to homeowners and a devastating pest ... a fungus that infects a common weed and found that ...
... ovarian cancer has shown single agent activity with durable disease ... international research group has reported. Dr Ursula Matulonis ... of the single-agent trial of the drug, called MLN8237, in ... for Medical Oncology (ESMO). MLN8237 selectively inhibits ...
Cached Biology News:Studies provide new insights into the genetics of obesity and fat distribution 2Studies provide new insights into the genetics of obesity and fat distribution 3Progress toward first commercial repellent for East Coast's stinker 2Investigational ovarian cancer drug shows promise against platinum resistant disease 2